-
DPP-4 inhibitors in the prevention/treatment of pulmonary fibrosis, heart and kidney injury caused by covid-19-a therapeutic approach of choice in type 2 diabetic patients? [Elektronski vir]Smelcerović, Andrija ...Since the outbreak of SARS-CoV-2 virus more than 12,500,000 cases have been reported worldwide. Patients suffering from diabetes and other comorbidities are particularly susceptible to severe forms ... of the COVID-19, which might result in chronic complications following recovery. Dipeptidyl peptidase-4 inhibitors exert beneficial effects in prevention/treatment of pulmonary fibrosis, heart, and kidney injury, and since they may be a long-term consequence caused by COVID-19, it is reasonable to expect that DPP-4 inhibitors might be beneficial in alleviating long-term consequences of COVID-19. With that in mind, we would like to voice our concerns over chronic implications following recovery from COVID-19, especially not only in diabetic but also in non-diabetic patients, and to indicate that some preventive measures could be undertaken by application of DPP-4 inhibitors.Vir: Frontiers in pharmacology [Elektronski vir]. - ISSN 1663-9812 (Vol. 11, 2020, str. 1-4)Vrsta gradiva - e-članek ; neleposlovje za odrasleLeto - 2020Jezik - angleškiCOBISS.SI-ID - 25125123
Avtor
Smelcerović, Andrija |
Kocić, Gordana |
Gajic, Mihajlo, farmacevt |
Tomović, Katarina |
Djordjevic, Vukica |
Stankovic-Djordjevic, Dobrila |
Anderluh, Marko
Teme
Sladkorna bolezen |
COVID-19 |
diabetes |
DPP-4 inhibitors |
fibrosis |
multi-organ injury |
poškodbe notranjih organov |
korona virus |
DPP-4 zaviralci |
pljučna fibroza
Avtor | Smelcerović, Andrija ... |
Naslov | DPP-4 inhibitors in the prevention/treatment of pulmonary fibrosis, heart and kidney injury caused by covid-19-a therapeutic approach of choice in type 2 diabetic patients? [Elektronski vir] |
Datum objave | 2020-08-05 |
COBISS.SI-ID | 25125123 |
Verzija objave v repozitoriju | Založnikova različica |
Licenca objave v repozitoriju | Creative Commons Priznanje avtorstva 4.0 Mednarodna |
Embargo | Takojšnja javna objava |
Projekti, iz katerih je bila financirana objava
Naziv | Akronim | Številka projekta | Financer |
---|---|---|---|
Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin | P1-0208-2015 |
Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije |
Datoteke, ki spadajo k objavi
Povezava |
---|
https://www.frontiersin.org/articles/10.3389/fphar.2020.01185/full |
https://repozitorij.uni-lj.si/IzpisGradiva.php?id=124557 |
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|---|
Smelcerović, Andrija | |
Kocić, Gordana | |
Gajic, Mihajlo, farmacevt | |
Tomović, Katarina | |
Djordjevic, Vukica | |
Stankovic-Djordjevic, Dobrila | |
Anderluh, Marko | 21456 |
Izberite prevzemno mesto:
Prevzem gradiva po pošti
Obvestilo
Gesla v Splošnem geslovniku COBISS
Izbira mesta prevzema
Mesto prevzema | Status gradiva | Rezervacija |
---|
Prosimo, počakajte trenutek.